Advice

Following a resubmission assessed under the end of life and ultra-orphan process:

axicabtagene ciloleucel (Yescarta®) is accepted for use within NHSScotland.

Indication under review: Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Axicabtagene ciloleucel was associated with an objective response rate of 82% in a single-arm, open-label, phase I/II study in patients with refractory DLBCL.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of axicabtagene ciloleucel. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
axicabtagene ciloleucel (Yescarta)
SMC ID:
SMC2189
Indication:

Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Accepted
Date advice published:
07 October 2019